Dextera Surgical (NASDAQ:DXTR) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday.

According to Zacks, “Dextera Surgical Inc. designs and manufactures proprietary stapling devices for surgical procedures. The company’s product consists of MicroCutter 5/80 use for transection and resection in urologic, thoracic and pediatric surgical procedures, as well as application for transection, resection and/or creation of anastomoses in the intestine and the transection of the appendix. Dextera Surgical Inc., formerly known as Cardica Inc., is headquartered in Redwood City, California. “

Separately, Ladenburg Thalmann Financial Services initiated coverage on Dextera Surgical in a research note on Wednesday, August 16th. They issued a “buy” rating and a $0.80 price target for the company.

Dextera Surgical (NASDAQ:DXTR) traded down $0.05 on Tuesday, hitting $0.09. The stock had a trading volume of 16,758,316 shares, compared to its average volume of 3,585,781. Dextera Surgical has a 12 month low of $0.08 and a 12 month high of $2.33.

Dextera Surgical (NASDAQ:DXTR) last posted its earnings results on Thursday, November 9th. The medical instruments supplier reported ($0.09) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.07) by ($0.02). The firm had revenue of $0.69 million during the quarter, compared to the consensus estimate of $0.62 million. research analysts forecast that Dextera Surgical will post -0.25 EPS for the current fiscal year.

A number of hedge funds have recently bought and sold shares of DXTR. Perkins Capital Management Inc. acquired a new position in Dextera Surgical in the second quarter valued at about $100,000. Virtu KCG Holdings LLC raised its stake in Dextera Surgical by 1,380.6% in the second quarter. Virtu KCG Holdings LLC now owns 369,918 shares of the medical instruments supplier’s stock valued at $111,000 after purchasing an additional 344,933 shares in the last quarter. Finally, Broadfin Capital LLC raised its stake in Dextera Surgical by 64.7% in the second quarter. Broadfin Capital LLC now owns 987,520 shares of the medical instruments supplier’s stock valued at $296,000 after purchasing an additional 388,080 shares in the last quarter. 4.49% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “Dextera Surgical (DXTR) Rating Increased to Hold at Zacks Investment Research” was first published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another site, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/12/12/dextera-surgical-dxtr-rating-increased-to-hold-at-zacks-investment-research.html.

About Dextera Surgical

Dextera Surgical Inc, formerly Cardica, Inc, designs and manufactures stapling devices that enable the advancement of minimally invasive surgical procedures. The Company is engaged in commercializing and developing its MicroCutter 5/80 stapler based on its staple-on-a-strip technology for use by thoracic, pediatric, bariatric, colorectal and general surgeons.

Get a free copy of the Zacks research report on Dextera Surgical (DXTR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Dextera Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dextera Surgical and related companies with MarketBeat.com's FREE daily email newsletter.